News & Updates
Filter by Specialty:

Lung cancer screening tied to reduced mortality
In an observational study conducted in Poland, individuals who participated in a low-dose computed tomography (LDCT) lung cancer screening programme had a reduction in all-cause mortality compared with a matched control group extracted from a general Polish cohort.
Lung cancer screening tied to reduced mortality
07 May 2024
Prognosis role of blood urea nitrogen to serum albumin ratio established in IPAH
A higher ratio of blood urea nitrogen to serum albumin is indicative of worse outcomes and disease severity in patients with idiopathic pulmonary arterial hypertension (IPAH), according to a study.
Prognosis role of blood urea nitrogen to serum albumin ratio established in IPAH
03 May 2024
Speeding COVID-19 symptom recovery may not fall within the realm of nirmatrelvir–ritonavir
Treating COVID-19 patients who had been vaccinated or did not have risk factors for severe disease with ritonavir-boosted nirmatrelvir (nirmatrelvir–ritonavir) did not expedite the time to symptom alleviation, reported investigators in the EPIC-SR trial.
Speeding COVID-19 symptom recovery may not fall within the realm of nirmatrelvir–ritonavir
30 Apr 2024
Supplement cocktail boosts COVID-19 treatment arsenal
Daily supplementation with melatonin, zinc, and multivitamins cuts the duration of COVID-19 or COVID-19-like symptoms, thus supplementing the COVID-19 treatment armamentarium, a study has shown.
Supplement cocktail boosts COVID-19 treatment arsenal
29 Apr 2024
Subcutaneous atezolizumab favoured over intravenous infusion
Nonsmall cell lung cancer (NSCLC) patients with high PD-L1 expression appear to show a strong preference for receiving atezolizumab subcutaneously rather than intravenously.
Subcutaneous atezolizumab favoured over intravenous infusion
18 Apr 2024
Anlotinib plus etoposide/carboplatin improves survival in extensive-stage SCLC
Use of anlotinib combined with etoposide and carboplatin (EC; chemotherapy) as first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC) yields a significantly improved progression-free survival (PFS) as well as overall survival (OS) benefits when compared with chemotherapy, according to data from the phase III ETER701 trial presented at ELCC 2024.